Abstracts Archive

Introduction: Targeted therapies may induce anti-tumor immune activation in r/r-TCL. We evaluated serial immunologic changes in patients with r/r-TCL treated on the phase 1 RAdR trial (NCT04447027).Methods: Patients with r/r-TCL received up to 6 cycles of RAdR. Peripheral blood was collected prior...

Background:Functional precision medicine evaluates drug response of patient's tumor cells to help guide treatment. This is particularly useful for T-cell lymphoma (TCL), which has limited treatment options. In a recent prospective study, Quadratic Phenotypic Optimization Platform (QPOP/Optim.AITM) w...

BackgroundAnti–PD-1 immunotherapy has demonstrated significant anti-tumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), achieving an objective response rate (ORR) of approximately 40% to 60% for single-agent therapy, but resistance remains a substantial challenge. Patients and...

Introduction: T-cell lymphomas (TCL) are highly aggressive with poor prognosis and limited treatment options. Epigenetic drugs such as the histone deacetylase inhibitor romidepsin and the DNA methyltransferase inhibitor azacytidine (Romi+AZA) synergize to reprogram tumor gene expression and impact ...

IntroductionAdult T-cell leukemia/lymphoma (ATLL) is an aggressive CD4⁺ T-cell malignancy linked to HTLV-1 infection, with limited therapeutic options and poor prognosis. CD70 is aberrantly expressed in ATLL and promotes immune evasion via CD27 signaling, making it a rational therapeutic target. C...

Background:North American Adult T-cell leukemia/lymphoma (NA-ATLL) is an aggressive HTLV-1–associated malignancy with median survival of less than one year. Interferon-alpha/Zidovudine in combination with other chemotherapy regimens showed efficacy in acute and chronic subtypes of ATLL. Our group ...